These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 32884129)

  • 1. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.
    Huang RSP; Haberberger J; Severson E; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Williams E; Elvin J; Vergilio JA; Killian JK; Lin DI; Tse J; Hiemenz M; Owens C; Danziger N; Hegde PS; Venstrom J; Alexander B; Ross JS; Ramkissoon SH
    Mod Pathol; 2021 Feb; 34(2):252-263. PubMed ID: 32884129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
    Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
    Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-cancer landscape of
    Huang RSP; Murugesan K; Montesion M; Pavlick DC; Mata DA; Hiemenz MC; Decker B; Frampton G; Albacker LA; Ross JS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
    Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
    JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer analysis of
    Huang RSP; Decker B; Murugesan K; Hiemenz M; Mata DA; Li G; Creeden J; Ramkissoon SH; Ross JS
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34130989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
    Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
    Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-cancer landscape of
    Kelly AD; Murugesan K; Kuang Z; Montesion M; Ross JS; Albacker LA; Huang RSP; Lin DI; Demirci U; Creeden J
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
    Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
    Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.
    Maule JG; Clinton LK; Graf RP; Xiao J; Oxnard GR; Ross JS; Huang RSP
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
    Huang RSP; Li X; Haberberger J; Sokol E; Severson E; Duncan DL; Hemmerich A; Edgerly C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Hiemenz M; Xiao J; McEwan D; Holmes O; Danziger N; Erlich R; Frampton G; Cohen MB; McGregor K; Reddy P; Cardeiro D; Anhorn R; Venstrom J; Alexander B; Brown C; Pusztai L; Ross JS; Ramkissoon SH
    Oncologist; 2020 Nov; 25(11):943-953. PubMed ID: 32869930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
    Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
    Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
    Zhou KI; Peterson B; Serritella A; Thomas J; Reizine N; Moya S; Tan C; Wang Y; Catenacci DVT
    Clin Cancer Res; 2020 Dec; 26(24):6453-6463. PubMed ID: 32820017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
    Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
    Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma.
    Huang RSP; Haberberger J; Murugesan K; Danziger N; Hiemenz M; Severson E; Duncan DL; Ramkissoon SH; Ross JS; Elvin JA; Lin DI
    Mod Pathol; 2021 Jul; 34(7):1425-1433. PubMed ID: 33637877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
    Danziger N; Sokol ES; Graf RP; Hiemenz MC; Maule J; Parimi V; Palmieri C; Pusztai L; Ross JS; Huang RSP
    Oncologist; 2023 Apr; 28(4):319-326. PubMed ID: 36866462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.